These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 31588878)
21. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Westlind-Johnsson A; Malmebo S; Johansson A; Otter C; Andersson TB; Johansson I; Edwards RJ; Boobis AR; Ingelman-Sundberg M Drug Metab Dispos; 2003 Jun; 31(6):755-61. PubMed ID: 12756208 [TBL] [Abstract][Full Text] [Related]
22. CYP3A5 variant allele frequencies in Dutch Caucasians. van Schaik RH; van der Heiden IP; van den Anker JN; Lindemans J Clin Chem; 2002 Oct; 48(10):1668-71. PubMed ID: 12324482 [TBL] [Abstract][Full Text] [Related]
23. Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma. Ohata Y; Shimada S; Akiyama Y; Mogushi K; Nakao K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M; Tanaka S Mol Cancer Ther; 2017 Jun; 16(6):1155-1165. PubMed ID: 28246302 [TBL] [Abstract][Full Text] [Related]
24. Effect of CYP3A5 gene polymorphisms on tacrolimus concentration/dosage ratio in adult liver transplant patients. Wang L; Liu LH; Tong WH; Wang MX; Lu SC Genet Mol Res; 2015 Nov; 14(4):15148-57. PubMed ID: 26634478 [TBL] [Abstract][Full Text] [Related]
25. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. Gebeyehu E; Engidawork E; Bijnsdorp A; Aminy A; Diczfalusy U; Aklillu E Pharmacogenomics J; 2011 Apr; 11(2):130-7. PubMed ID: 20231858 [TBL] [Abstract][Full Text] [Related]
26. p53 and P-glycoprotein influence chemoresistance in hepatocellular carcinoma. Li S; Gao M; Li Z; Song L; Gao X; Han J; Wang F; Chen Y; Li W; Yang J Front Biosci (Elite Ed); 2018 Jun; 10(3):461-468. PubMed ID: 29772519 [TBL] [Abstract][Full Text] [Related]
27. Development and validation of a rapid and reliable real-time PCR method for CYP3A5 genotyping. Eidens M; Weise A; Klemm M; Fleischer M; Prause S Clin Lab; 2015; 61(3-4):353-62. PubMed ID: 25975003 [TBL] [Abstract][Full Text] [Related]
28. Role of microRNAs in the development of hepatocellular carcinoma and drug resistance. Tricoli L; Niture S; Chimeh U; Ressom H; Kumar D Front Biosci (Landmark Ed); 2019 Jan; 24(2):382-391. PubMed ID: 30468662 [TBL] [Abstract][Full Text] [Related]
29. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients. Monostory K; Tóth K; Kiss Á; Háfra E; Csikány N; Paulik J; Sárváry E; Kóbori L Br J Clin Pharmacol; 2015 Dec; 80(6):1429-37. PubMed ID: 26271661 [TBL] [Abstract][Full Text] [Related]
30. Role of microRNAs in the development of hepatocellular carcinoma and acquired drug resistance. Tricoli L; Niture S; Chimeh U; Kumar D Front Biosci (Landmark Ed); 2019 Jan; 24(3):545-554. PubMed ID: 30468672 [TBL] [Abstract][Full Text] [Related]
31. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056 [TBL] [Abstract][Full Text] [Related]
32. Dysregulation of non-coding RNAs mediates cisplatin resistance in hepatocellular carcinoma and therapeutic strategies. Xu XF; Yang XK; Song Y; Chen BJ; Yu X; Xu T; Chen ZL Pharmacol Res; 2022 Feb; 176():105906. PubMed ID: 34543740 [TBL] [Abstract][Full Text] [Related]
33. Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population. Krasniqi V; Dimovski A; Bytyqi HQ; Eftimov A; Šimičević L; Božina N Arh Hig Rada Toksikol; 2017 Sep; 68(3):180-184. PubMed ID: 28976882 [TBL] [Abstract][Full Text] [Related]
34. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. de Jonge H; Metalidis C; Naesens M; Lambrechts D; Kuypers DR Pharmacogenomics; 2011 Sep; 12(9):1281-91. PubMed ID: 21770725 [TBL] [Abstract][Full Text] [Related]
35. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy? Bedewy AM; El-Maghraby SM Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475 [TBL] [Abstract][Full Text] [Related]